Blog
About

0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Cerebral Blood Flow, Cerebral Blood Flow Reactivity to Acetazolamide, and Cerebral Blood Volume in Patients with Leukoaraiosis

      Read this article at

      ScienceOpenPublisher
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          We have used single photon emission computed tomography to study cerebral blood flow (CBF), CBF reactivity to acetazolamide, and cerebral blood volume (CBV) in 15 subjects presenting widespread leukoaraiosis, with the aim of answering the question if chronic ischaemia or hypo metabolism is associated with leukoaraiosis. We compared these subjects to 9 controls presenting no leukoaraiosis but with similarly distributed factors for leukoaraiosis. The subjects with leukoaraiosis showed a low regional (r)CBF in their white matter, while CBV and CBF reactivity to acetazolamide were not significantly affected. rCBF, rCBV and rCBF reactivity to acetazolamide did not differ between the cortex of patients and controls. Our results suggest that the low white matter CBF of the patients with leukoaraiosis was related mainly to hypometabolism and not to oligaemia. The capacity of the cerebral vessels to vasodilate does not appear to be affected by leukoaraiosis.

          Related collections

          Author and article information

          Journal
          CED
          Cerebrovasc Dis
          10.1159/issn.1015-9770
          Cerebrovascular Diseases
          S. Karger AG
          1015-9770
          1421-9786
          1994
          1994
          25 May 1994
          : 4
          : 4
          : 287-293
          Affiliations
          a Department of Neurology, b INSERM U 230, and c Department of Neuroradiology, Hôpital Purpan, Toulouse, France
          Article
          108496 Cerebrovasc Dis 1994;4:287–293
          10.1159/000108496
          © 1994 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 7
          Categories
          Original Paper

          Comments

          Comment on this article